Faber, J; Armstrong, SA
Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies.Klin Padiatr. Bd. 219. H. 6. 2007 S. 306-11
Lukacs, Z; Hartung, R; Beck, M et al.
Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patientsJ Inherit Metab Dis. Bd. 30. H. 4. 2007 S. 614
Wessler, I; Bittinger, F; Kamin, W et al.
Dysfunction of the non-neuronal cholinergic system in the airways and blood cells of patients with cystic fibrosis.Life Sci. Bd. 80. H. 24-25. 2007 S. 2253-8
Ullmann, AJ; Krammes, E; Sommer, S et al.
Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.J Antimicrob Chemother. Bd. 60. H. 5. 2007 S. 1080-4
Ries, M; Clarke, JT; Whybra, C et al.
Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.J Clin Pharmacol. Bd. 47. H. 10. 2007 S. 1222-30
Wraith, JE; Beck, M; Lane, R et al.
Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).Pediatrics. Bd. 120. H. 1. 2007 S. e37-46
Ramaswami, U; Wendt, S; Pintos-Morell, G et al.
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.Acta Paediatr Suppl. Bd. 96. 2007 S. 122-127
Thiesen, J; Höpner, J; Schulte, A et al.
Erstellung einer Kompatibilitätstabelle für die intravenöse Pharmakotherapie auf neonatologischen und pädiatrischen IntensivstationenKlin Padiatr. H. 219. 2007 S. 37-43
Hoepner, JH; Schulte, A; Thiessen, J et al.
Erstellung einer Kompatibilitatstabelle für die intravenose Pharmakotherapie auf neonatologischen und padiatrischen Intensivstationen.Klin Padiatr. Bd. 219. H. 1. 2007 S. 37-43
Müllens, M; Butzer, R; Seibert-Grafe, M et al.
EU Verordnung über Kinderarzneimittel. Mehr Sicherheit.Dtsch Arztebl. Bd. 104. H. 5. 2007 S. 202-203